Silexion Therapeutics (SLXN)

• Market cap: $5.72M
• 1 day: -6.63%
• 5 days: -16.82%
• 1 month: 5.78%
• 3 months: -44.55%
• 6 months: -83.83%
• Year to date: -2.66%
• 1 year: -94.05%
• 5 years: -99.3%
• 10 years: -99.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Employees: 14